Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Cinrebafusp alfa by Pieris Pharmaceuticals for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Human Epidermal Growth Factor Receptor...
Cinrebafusp alfa by Pieris Pharmaceuticals for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction....
Cinrebafusp alfa by Pieris Pharmaceuticals for Gastric Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Gastric Cancer. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Gynecological Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Gynecological Cancer. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Vulvar Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Vulvar Cancer. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Endometrial Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Endometrial Cancer. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Bladder Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Bladder Cancer. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Solid Tumor: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Rectal Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Rectal Cancer. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...
Cinrebafusp alfa by Pieris Pharmaceuticals for Esophageal Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Esophageal Cancer. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Pancreatic Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Pancreatic Cancer. According to GlobalData,...
Cinrebafusp alfa by Pieris Pharmaceuticals for Colorectal Cancer: Likelihood of Approval
Cinrebafusp alfa is under clinical development by Pieris Pharmaceuticals and currently in Phase I for Colorectal Cancer. According to GlobalData,...